Cheelcare Signs Five-Year Lease for New Manufacturing Facility to Support Growth
This expansion is a critical step in sustaining the Company's rapid growth, enabling Cheelcare to significantly improve production capacity for its flagship Companion power assist product, while also establishing a dedicated production line for Curio, its patented omni-directionally tilting complex rehab power wheelchair.
The newly renovated facility offers greater flexibility for research and development, manufacturing, assembly, and warehousing operations, as well as office space for staff and a dedicated space for product education. Located just minutes from Highways 404, 407, and 7, the site offers efficient access to suppliers, logistics partners, and dealer networks.
"Securing this new space is the catalyst of our growth strategy," said
The lease term commences on
About Cheelcare Inc.
Cheelcare designs and manufactures innovative mobility solutions that empower independence for people with disabilities. From the Companion power assist devices to the groundbreaking Curio robotic wheelchair, Cheelcare combines engineering excellence with human-centered design to improve quality of life.
For more information, please visit: www.cheelcare.ca
Forward-Looking Information
This news release contains forward-looking statements, including statements regarding the expected benefits of the new facility, anticipated improvements to production capabilities, and the potential market demand for the Company's products. These forward-looking statements are based on current expectations and involve known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those expressed or implied. Such factors include, but are not limited to, general economic conditions, market demand, supply chain disruptions, and regulatory approvals. Forward-looking statements are made as of the date of this news release, and the Company does not undertake to update any forward-looking statements except in accordance with applicable securities laws.
Neither the
SOURCE